We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
340.85%
This Fund
S&P 500
This Quarter
Est. Return
+8.25%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
(+25%)
Cap. Flow
+$320M
Cap. Flow
% of AUM
18.81%
Top 10 Holdings %
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
+$40.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.1M |
| 3 |
Denali Therapeutics
DNLI
|
+$36.2M |
| 4 |
Inspire Medical Systems
INSP
|
+$27.3M |
| 5 |
Vir Biotechnology
VIR
|
+$21.9M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$39.4M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$17.3M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$13.2M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$10.4M |
| 5 |
Arbutus Biopharma
ABUS
|
+$9.98M |
Sector Composition
| 1 | Healthcare | 88.42% |
| 2 | Financials | 1.51% |
| 3 | Technology | 0.08% |
| 4 | Industrials | 0.08% |
| 5 | Materials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Neurocrine Biosciences
NBIX
$17.3B
| $329K | 0.02% |
+2,500
| New | +$332K |
|
227
CALL
Corbus Pharmaceuticals
CRBP
$162M
| $329K | 0.02% |
+35,000
| New | +$295K |
|
228
Wave Life Sciences
WVE
$1.08B
| $326K | 0.02% |
+44,900
| New | +$585K |
|
229
Kura Oncology
KURA
$960M
| $325K | 0.02% |
40,000
| – | – |
|
230
Kiora Pharmaceuticals
KPRX
$11.3M
| $324K | 0.02% |
167,941
| – | – |
|
231
Corcept Therapeutics
CORT
$9.74B
| $322K | 0.02% |
+8,000
| New | +$299K |
|
|
UPB
232
Upstream Bio Inc
UPB
$385M
| $315K | 0.02% |
+35,000
| New | +$630K |
|
233
OrthoPediatrics
KIDS
$526M
| $315K | 0.02% |
19,845
| – | – |
|
234
Annexon
ANNX
$963M
| $305K | 0.02% |
55,000
+7,000
| +15% | +$39.4K |
|
235
Geron
GERN
$911M
| $298K | 0.02% |
200,000
-136,176
| -41% | -$207K |
|
236
JD.com
JD
$40.2B
| $296K | 0.02% |
10,000
| – | – |
|
237
PMV Pharmaceuticals
PMVP
$68.3M
| $286K | 0.02% |
231,008
+130,000
| +129% | +$165K |
|
238
Traws Pharma
TRAW
$10.3M
| $282K | 0.02% |
154,098
-333
| -0.2% | -$626 |
|
|
JBIO
239
Jade Biosciences
JBIO
$1.26B
| $281K | 0.02% |
20,000
-1,000
| -5% | -$14.5K |
|
240
Ultragenyx Pharmaceutical
RARE
$2.96B
| $281K | 0.02% |
+13,400
| New | +$302K |
|
|
PCAPU
241
ProCap Acquisition Corp Unit
PCAPU
| $279K | 0.02% |
26,940
| – | – |
|
|
BCAX
242
Bicara Therapeutics
BCAX
$1.79B
| $273K | 0.02% |
13,705
| – | – |
|
243
RxSight
RXST
$234M
| $266K | 0.02% |
43,250
+21,447
| +98% | +$178K |
|
244
Palo Alto Networks
PANW
$287B
| $257K | 0.02% |
+1,600
| New | +$269K |
|
245
Intellia Therapeutics
NTLA
$1.65B
| $250K | 0.01% |
+19,517
| New | +$249K |
|
246
CrowdStrike
CRWD
$207B
| $250K | 0.01% |
+2,560
| New | +$271K |
|
247
Rubrik
RBRK
$16.5B
| $240K | 0.01% |
+4,900
| New | +$281K |
|
248
Royalty Pharma
RPRX
$25.8B
| $240K | 0.01% |
+5,000
| New | +$219K |
|
249
Surgery Partners
SGRY
$2.18B
| $238K | 0.01% |
20,000
| – | – |
|
250
Larimar Therapeutics
LRMR
$368M
| $237K | 0.01% |
52,745
-132,944
| -72% | -$531K |
|
Similar funds
RSCM
AAM
SGI
WAS
BCM
SWM
TCM
ISS